A Drug Utilization Study on Pharmaceutical Preparations for Scabies : The Prevalence of Scabies and its Management
In Japan, no report has so far been published which evaluates drug use for scabies. We surveyed the prevalence of scabies and its management. The result showed that scabies is not a rare contagious parasitic skin infection. Since there is no effective and safe drug for scabies on the market, the fol...
Saved in:
| Published in | Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) Vol. 29; no. 5; pp. 665 - 670 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
Japanese Society of Pharmaceutical Health Care and Sciences
2003
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1346-342X 1882-1499 1882-1499 |
| DOI | 10.5649/jjphcs.29.665 |
Cover
| Abstract | In Japan, no report has so far been published which evaluates drug use for scabies. We surveyed the prevalence of scabies and its management. The result showed that scabies is not a rare contagious parasitic skin infection. Since there is no effective and safe drug for scabies on the market, the following medications were found to be used for its treatment : crotamiton (unlabeled use), Benzyl benzoate formulation (compounded), γ-BHC formulation (compounded). Adverse events associated with those drugs were also reported. In most case, the patients did not receive adequate counseling regarding their drug therapy. Physicians and other health care professionals have been frustrated by the lack of effective preventive and therapeutic intervention for scabies. It is therefore necessary to approve a drug to treat scabies and to also establish clear guidelines for the treatment and management of scabies. |
|---|---|
| AbstractList | In Japan, no report has so far been published which evaluates drug use for scabies. We surveyed the prevalence of scabies and its management. The result showed that scabies is not a rare contagious parasitic skin infection. Since there is no effective and safe drug for scabies on the market, the following medications were found to be used for its treatment : crotamiton (unlabeled use), Benzyl benzoate formulation (compounded), γ-BHC formulation (compounded). Adverse events associated with those drugs were also reported. In most case, the patients did not receive adequate counseling regarding their drug therapy. Physicians and other health care professionals have been frustrated by the lack of effective preventive and therapeutic intervention for scabies. It is therefore necessary to approve a drug to treat scabies and to also establish clear guidelines for the treatment and management of scabies. |
| Author | Sugiyama, Tadashi Masada, Mikio Shiraishi, Tadashi Yamakawa, Masayuki Goto, Nobuyuki Suda, Noriyuki Nakayama, Kazuhiko Komoda, Masayo |
| Author_xml | – sequence: 1 fullname: Goto, Nobuyuki organization: Department of Hospitai Pharmacy, Fukui Medicai University – sequence: 1 fullname: Komoda, Masayo organization: Department of Pharmacy, Kashiwakouyo Hospital – sequence: 1 fullname: Nakayama, Kazuhiko organization: Department of Pharmacy, School of Medicine, Keio University – sequence: 1 fullname: Shiraishi, Tadashi organization: Department of Pharmacy, Yamagata University Hospital – sequence: 1 fullname: Sugiyama, Tadashi organization: Department of Pharmacy, Gifu University Hospital – sequence: 1 fullname: Masada, Mikio organization: Department of Hospitai Pharmacy, Fukui Medicai University – sequence: 1 fullname: Suda, Noriyuki organization: Department of Pharmacy, Hokkaido University Hospitai – sequence: 1 fullname: Yamakawa, Masayuki organization: Department of Hospital Pharmacy, Shiga Medical University |
| BookMark | eNqFkU1LAzEQhoMo-Hn0nj-wdfPpxpv4DRULVfC2zGYTm7LNliRV6q83daUHQbzMDMz7TODJIdr1vTcInZJyJCRXZ_P5cqbjiKqRlGIHHZCqogXhSu3mmXFZME5f99FJjK4pS0aIJEIdoHCJr8PqDb8k17lPSK73eJpW7RrnYTKDsABtVslp6PAkmCWE70zEtg94qqFxJuIL_Dwzm_U7dMZrg3u73YFvsUsRP4KHN7MwPh2jPQtdNCc__Qi93N48X90X46e7h6vLcaEpJ6KgligrGlkJwZQuWwZc6POWMNZoJXJlwmjLOWfSVpY2VBOQbUsaWWoJrGJHaDTcXfklrD-g6-plcAsI65qU9UZaPUirqaqztAwUA6BDH2Mw9t88-5XXLn3rSQFc9yd1O1DzmLKR7RsQsuXO_KRpWZINIYaSwW1A51-pjWdfi9ueWQ |
| CitedBy_id | crossref_primary_10_1111_j_1346_8138_2008_00491_x |
| ContentType | Journal Article |
| Copyright | Japanese Society of Pharmaceutical Health Care and Sciences |
| Copyright_xml | – notice: Japanese Society of Pharmaceutical Health Care and Sciences |
| DBID | AAYXX CITATION ADTOC UNPAY |
| DOI | 10.5649/jjphcs.29.665 |
| DatabaseName | CrossRef Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1882-1499 |
| EndPage | 670 |
| ExternalDocumentID | 10.5649/jjphcs.29.665 10_5649_jjphcs_29_665 article_jjphcs2001_29_5_29_5_665_article_char_en |
| GroupedDBID | .LE 5GY ABJNI ALMA_UNASSIGNED_HOLDINGS KQ8 MOJWN RJT AAYXX CITATION ADTOC UNPAY |
| ID | FETCH-LOGICAL-c2415-2f19f5b685539c0d3a45c7d133bc9533b35ecf44436f8f2b2c1a6dd1b60c6a383 |
| IEDL.DBID | UNPAY |
| ISSN | 1346-342X 1882-1499 |
| IngestDate | Thu Aug 28 11:03:10 EDT 2025 Tue Jul 01 01:53:24 EDT 2025 Thu Apr 24 23:01:45 EDT 2025 Wed Sep 03 06:30:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 5 |
| Language | Japanese |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2415-2f19f5b685539c0d3a45c7d133bc9533b35ecf44436f8f2b2c1a6dd1b60c6a383 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/jjphcs2001/29/5/29_5_665/_pdf |
| PageCount | 6 |
| ParticipantIDs | unpaywall_primary_10_5649_jjphcs_29_665 crossref_primary_10_5649_jjphcs_29_665 crossref_citationtrail_10_5649_jjphcs_29_665 jstage_primary_article_jjphcs2001_29_5_29_5_665_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2003 |
| PublicationDateYYYYMMDD | 2003-01-01 |
| PublicationDate_xml | – year: 2003 text: 2003 |
| PublicationDecade | 2000 |
| PublicationTitle | Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) |
| PublicationTitleAlternate | Jpn. J. Pharm. Health Care Sci. |
| PublicationYear | 2003 |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Publisher_xml | – name: Japanese Society of Pharmaceutical Health Care and Sciences |
| References | 2) 樹神元博, 小林誠一郎, 谷川瑛子, 竹内勤, 座覇修, 斎藤厚, 田中勝, 西川武二, 疥癬に対するイベルメクチンの効果-1例報告と当科における25例の検討, 臨床皮膚科, 55, 2735276 (2001). 3) 後藤伸之, 須田範行, 白石正, 小茂田昌代, 中山和彦, 杉山正, 山川雅之, 政田幹夫, 院内製剤の市販化に向けた調査研究, 日病薬誌, 39, 88-90 (2003). 19) 玉井郁巳, 辻彰, 血液脳関門と薬物脳内移行, 医学のあゆみ, 179,383-387 (1996). 10) E.N. Chouela, A.M. Abeldano, G. Pellerano, M.La Forgia, R.M. Papale, A. Garsd, M.C. Balian, V. Battista, N. Poggio, Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies, Arch. Dermatol., 135,651-655 (1999). 14) J.A. Diazgranados, J.L. Costa., Deaths after ivermectin treatment, Lancet, 349, 1698 (1997). 1) 大滝倫子, 疥癬の現況と対応, 皮膚科の臨床, 41, 1069-1075 (1999). 18) Z. Zeng, N.W. Andrew, B.H. Arison, D.Luffer-Atlas, R.W. Wang, Identification of cytochrome P4503A 4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes, Xenobiotica, 28,313-321 (1998 16) 小松崎眞, 中澤靖, 吉川晃司, 柴孝也, 小野寺昭一, 大友弘士, 疥癬集団発生事例に対するイベルメクチンの使用経験について, 日本化学療法学会雑誌, 50 (suppl-A), 184 (2002). 7) 日本クリニカルエビデンス編集委員会編, “疥癬, クリニカル・エビデンス日本語版2002-2003”, 日経BP社, 東京, 2002, pp. 1467-1473. 11) P. Glaziou, J.L. Cartel, P. Alzieu, C. Briot, J.P. Moulia-Pelat, P.M. Martin, Comparison of ivermectin and benzyl benzoate for treatment of scabies, Trop. Med. Parasitol., 44,331-332 (1993). 13) R. Barkwell, S. Shields, Deaths associated with ivermectin treatment of scabies, Lancet, 349, 1144-1145 (1997). 15) 内間庸文, 仲地紀哉, 平田哲生, 座覇修, 金城渚, 佐久川廣, 金城福則, 斎藤厚, 疥癬に対するivermectin経口投与の有効性の検討, 感染症学雑誌, 76,683 (2002). 12) M. Pacque, B. Munoz, G. Poetschke, J. Foose, B.M. Greene, H.R. Taylor, Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution, Lancet, 336, 1486-1489 (1990). 6) 出雲正剛, 橋本正良監修, “日本語版サンフォード感染症治療ガイド2002 (第32版)”, ライスサイエンス出版, 東京, 2002, pp. 192-193. 9) T.L. Meinking, D. Taplin, J.L. Hermida, R. Pardo, F. A. Kerdel, The treatment of scabies with ivermectin, N. Engl. J. Med., 333, 26-30 (1995 17) J. Gardon, N. Gardon-Wendel, Demanga-Ngangue, J. Kamgno, J.P. Chippaux, M. Boussinesq, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection, Lancet, 350, 18-22 (1997). 4) 大滝倫子, 老人福祉施設における疥癬の現況, 皮膚病診療, 19,468-472 (1997). 5) G.R.Scott, Europian guideline for the management of scabies, International Journal of STD & AIDS, 12 (Suppl.3), 58-61 (2001). 8) 大滝倫子, 疥癬の診断・治療・対策, 日本医事新報, 3994, 8-14 (2000). |
| References_xml | – reference: 12) M. Pacque, B. Munoz, G. Poetschke, J. Foose, B.M. Greene, H.R. Taylor, Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution, Lancet, 336, 1486-1489 (1990). – reference: 14) J.A. Diazgranados, J.L. Costa., Deaths after ivermectin treatment, Lancet, 349, 1698 (1997). – reference: 16) 小松崎眞, 中澤靖, 吉川晃司, 柴孝也, 小野寺昭一, 大友弘士, 疥癬集団発生事例に対するイベルメクチンの使用経験について, 日本化学療法学会雑誌, 50 (suppl-A), 184 (2002). – reference: 2) 樹神元博, 小林誠一郎, 谷川瑛子, 竹内勤, 座覇修, 斎藤厚, 田中勝, 西川武二, 疥癬に対するイベルメクチンの効果-1例報告と当科における25例の検討, 臨床皮膚科, 55, 2735276 (2001). – reference: 13) R. Barkwell, S. Shields, Deaths associated with ivermectin treatment of scabies, Lancet, 349, 1144-1145 (1997). – reference: 8) 大滝倫子, 疥癬の診断・治療・対策, 日本医事新報, 3994, 8-14 (2000). – reference: 7) 日本クリニカルエビデンス編集委員会編, “疥癬, クリニカル・エビデンス日本語版2002-2003”, 日経BP社, 東京, 2002, pp. 1467-1473. – reference: 9) T.L. Meinking, D. Taplin, J.L. Hermida, R. Pardo, F. A. Kerdel, The treatment of scabies with ivermectin, N. Engl. J. Med., 333, 26-30 (1995) – reference: 10) E.N. Chouela, A.M. Abeldano, G. Pellerano, M.La Forgia, R.M. Papale, A. Garsd, M.C. Balian, V. Battista, N. Poggio, Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies, Arch. Dermatol., 135,651-655 (1999). – reference: 3) 後藤伸之, 須田範行, 白石正, 小茂田昌代, 中山和彦, 杉山正, 山川雅之, 政田幹夫, 院内製剤の市販化に向けた調査研究, 日病薬誌, 39, 88-90 (2003). – reference: 17) J. Gardon, N. Gardon-Wendel, Demanga-Ngangue, J. Kamgno, J.P. Chippaux, M. Boussinesq, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection, Lancet, 350, 18-22 (1997). – reference: 11) P. Glaziou, J.L. Cartel, P. Alzieu, C. Briot, J.P. Moulia-Pelat, P.M. Martin, Comparison of ivermectin and benzyl benzoate for treatment of scabies, Trop. Med. Parasitol., 44,331-332 (1993). – reference: 5) G.R.Scott, Europian guideline for the management of scabies, International Journal of STD & AIDS, 12 (Suppl.3), 58-61 (2001). – reference: 1) 大滝倫子, 疥癬の現況と対応, 皮膚科の臨床, 41, 1069-1075 (1999). – reference: 6) 出雲正剛, 橋本正良監修, “日本語版サンフォード感染症治療ガイド2002 (第32版)”, ライスサイエンス出版, 東京, 2002, pp. 192-193. – reference: 15) 内間庸文, 仲地紀哉, 平田哲生, 座覇修, 金城渚, 佐久川廣, 金城福則, 斎藤厚, 疥癬に対するivermectin経口投与の有効性の検討, 感染症学雑誌, 76,683 (2002). – reference: 19) 玉井郁巳, 辻彰, 血液脳関門と薬物脳内移行, 医学のあゆみ, 179,383-387 (1996). – reference: 18) Z. Zeng, N.W. Andrew, B.H. Arison, D.Luffer-Atlas, R.W. Wang, Identification of cytochrome P4503A 4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes, Xenobiotica, 28,313-321 (1998) – reference: 4) 大滝倫子, 老人福祉施設における疥癬の現況, 皮膚病診療, 19,468-472 (1997). |
| SSID | ssib003116159 ssib002484604 ssib000871962 ssib060196744 ssj0069027 ssib005902156 ssib023157658 |
| Score | 1.5097643 |
| Snippet | In Japan, no report has so far been published which evaluates drug use for scabies. We surveyed the prevalence of scabies and its management. The result showed... |
| SourceID | unpaywall crossref jstage |
| SourceType | Open Access Repository Enrichment Source Index Database Publisher |
| StartPage | 665 |
| SubjectTerms | antiscabietic drug Utilization Study Hospital Preparation pharmacoepidemiology scabies |
| Title | A Drug Utilization Study on Pharmaceutical Preparations for Scabies : The Prevalence of Scabies and its Management |
| URI | https://www.jstage.jst.go.jp/article/jjphcs2001/29/5/29_5_665/_article/-char/en https://www.jstage.jst.go.jp/article/jjphcs2001/29/5/29_5_665/_pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2003/10/10, Vol.29(5), pp.665-670 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1882-1499 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0069027 issn: 1346-342X databaseCode: KQ8 dateStart: 20010101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xXSTgwHPRlsfKB1QuTdL61YQLqoDVCqRVEVupnKzYscuWKs22qVD59dix-xASCIlLYsmjxJmZ2N9YM58BXlGGKZNYRyknJqKEsihjmkeKWvRONCGFbLItLvnFmH6csMlBLYxLq5xZXDTV7hZPF_GsSoISk9ms-qZWLgsowVnC7EUwwTlLRFWYIzjmzOLxFhyPL0fDr02kRXlEKJ64toOSNhzIPNEm4zQLz4txFnO3uBwsTLf9GO7BnXVZ5Zsf-Xx-sOycPwC1HbDPNvker2sZq5-_cTn-3xc9hPsBlaKhl38Et3T5GDojT2u96aKrfZXWqos6aLQnvN48gZsher9cT9G4vp6Hsk7k8hM3yDaCaNg0R6Ol9mzj1tuRBczoi8qljdbfuHe4Xuv5brJBC7PtQnlZoOt6hfapOicwPv9w9e4iCkc5RMpBhAibfmaY5CljJFO9guSUqUFhA2SpXIKrJEwrQ617cJMaLLHq57wo-pL3FM9tFP0UWuWi1KeA6MConlTMgSmqdZr3c6oULgZaSkfg1Ybu1o5CBZ5zd9zGXNh4x5ldeKULq2ur6TZ0duKVJ_j4k-Bbb8adWDCi2BtRNPbbGnEn4Aro7CzUhtc7b_r7u579s-RzuNukFzabQi-gVS_X-qWFSbU8g6NPn9Oz8Df8AtVZFds |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Li9swEBZtttD20HfZ9IUOJb3EdqJX4l5KaLssPSyBbiA9CUmWspsGx5s4lPTXd2QpDwothV5sgQZbnhlL34iZTwi9ZZwwrolNhoK6hFHGk5xbkRgG6J1aSgvdZFtciPMJ-zLl06NaGJ9WOQdcNLP-ls6W6bzKohKz-by6MmufBZSRPONwkVwKwTNZFe42OhEc8HgLnUwuxqNvTaTFREIZmfq2h5IQDuSBaJMLlsfnpSRPhV9cjhamO2EM99HdTVmp7Q-1WBwtO2cPkdkNOGSbfE83tU7Nz9-4HP_vix6hBxGV4lGQf4xu2fIJ6owDrfW2iy8PVVrrLu7g8YHwevsU3Yzwp9Vmhif19SKWdWKfn7jF0IiicdMcj1c2sI2Dt2MAzPirURqi9ff-Hb4XPN9PNnjpdl1YlQW-rtf4kKrzDE3OPl9-PE_iUQ6J8RAhIa6fO67FkHOam15BFeNmUECArI1PcNWUW-MYuIdwQ0c0MX0liqKvRc8IBVH0c9Qql6U9RZgNnOlpwz2YYtYOVV8xY0gxsFp7Aq826u7sKE3kOffHbSwkxDve7DIoXYKuQdNt1NmLV4Hg40-CH4IZ92LRiPJgRNnYb2fEvYAvoINZqI3e7b3p7-968c-SL9G9Jr2w2RR6hVr1amNfA0yq9Zv4H_wCV_IU5g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Drug+Utilization+Study+on+Pharmaceutical+Preparations+for+Scabies+%3A+The+Prevalence+of+Scabies+and+its+Management&rft.jtitle=Iryo+Yakugaku+%28Japanese+Journal+of+Pharmaceutical+Health+Care+and+Sciences%29&rft.au=Goto%2C+Nobuyuki&rft.au=Komoda%2C+Masayo&rft.au=Nakayama%2C+Kazuhiko&rft.au=Shiraishi%2C+Tadashi&rft.date=2003&rft.pub=Japanese+Society+of+Pharmaceutical+Health+Care+and+Sciences&rft.issn=1346-342X&rft.eissn=1882-1499&rft.volume=29&rft.issue=5&rft.spage=665&rft.epage=670&rft_id=info:doi/10.5649%2Fjjphcs.29.665&rft.externalDocID=article_jjphcs2001_29_5_29_5_665_article_char_en |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1346-342X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1346-342X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1346-342X&client=summon |